LABP — Landos Biopharma Income Statement
0.000.00%
- $69.71m
- $40.70m
- 20
- 12
- 93
- 37
Annual income statement for Landos Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 18 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 13.3 | 30.7 | 56.8 | 40.6 | 22.7 |
Operating Profit | -13.3 | -30.7 | -38.8 | -40.6 | -22.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -13.5 | -30.1 | -38.4 | -39.3 | -21.9 |
Net Income After Taxes | -13.5 | -30.1 | -38.4 | -39.3 | -21.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -13.5 | -30.1 | -38.4 | -39.3 | -21.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -13.5 | -30.1 | -38.4 | -39.3 | -21.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.44 | -7.51 | -10.2 | -9.68 | -3.5 |
Dividends per Share |